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The plasminogen receptors mediate the production and localization to the cell surface of the broad spectrum proteinase,
plasmin. S100A10 is a key regulator of cellular plasmin production and may account for as much as 50% of cellular plasmin
generation. In parallel to plasminogen, the plasminogen-binding site on S100A10 is highly conserved from mammals to fish.
S100A10 is constitutively expressed in many cells and is also induced by many diverse factors and physiological stimuli including
dexamethasone, epidermal growth factor, transforming growth factor-α, interferon-γ, nerve growth factor, keratinocyte growth
factor, retinoic acid, and thrombin. Therefore, S100A10 is utilized by cells to regulate plasmin proteolytic activity in response to
a wide diversity of physiological stimuli. The expression of the oncogenes, PML-RARα and KRas, also stimulates the levels of
S100A10, suggesting a role for S100A10 in pathophysiological processes such as in the oncogenic-mediated increases in plasmin
production. The S100A10-null mouse model system has established the critical role that S100A10 plays as a regulator of fibrinolysis
and oncogenesis. S100A10 plays two major roles in oncogenesis, first as a regulator of cancer cell invasion and metastasis and
secondly as a regulator of the recruitment of tumor-associated cells, such as macrophages, to the tumor site.
1. Introduction
Several fundamental studies have shown that cellular recep-
tors for plasminogen play a major role in the regulation of
important physiological processes such as fibrinolysis and
in the development of disease, such as cancer [1–4]. The
binding of the blood protein and zymogen, plasminogen, to
specific cell surface receptors, called plasminogen receptors,
significantly increases the rate of its proteolytic conversion
to plasmin, due to the colocalization of plasminogen with
its activators, tissue plasminogen activator (tPA) and the
urokinase-type plasminogen activator (uPA) [5, 6]. Although
tPA shares the same cellular binding sites as plasminogen [7–
9], uPA is localized to the cell surface by its binding to its cell
surface receptor, the urokinase-type plasminogen receptor
(uPAR) [10]. Many intracellular and extracellular functions
have been proposed for S100A10, of which probably the
most striking in terms of physiological significance and
implications for disease is the extracellular function of
this protein as a plasminogen receptor (reviewed in [11–
14]). S100A10 binds to tPA and plasminogen and also
colocalizes with the uPA/uPAR complex, which stimulates
the conversion of plasminogen to the broad specificity
protease, plasmin. Plasmin also binds to S100A10 which
protects the newly generated plasmin from inactivation
by its inhibitor, α2-antiplasmin, and also serves to focus
the proteolytic activity of plasmin to the cell surface [15].
S100A10 also stimulates plasmin autoproteolysis, resulting in
the destruction of plasmin and the generation of bioactive
plasmin fragments, the angiostatins (reviewed in [16]). A
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main characteristic of the plasminogen receptors is the
presence of a carboxyl-terminal lysine residue that binds to
the kringle domains of plasminogen [9, 13, 17, 18]. S100A10
possesses two carboxyl-terminal lysine residues that have
been shown to bind both tPA and plasminogen and to play
a critical role in the conversion of plasminogen to plasmin
by the plasminogen activators [19, 20]. Several plasminogen
receptors have been reported that do not contain a carboxyl-
terminal lysine residue, but it is unclear as to what extent
these proteins contribute to cellular plasmin generation.
In this paper we will review, in detail, the structure
and function of S100A10. Although both intracellular [21,
22] and extracellular roles [12] have been identified for
S100A10, the main focus of this paper will be on the
extracellular role of S100A10 as a plasminogen receptor.
We will develop two themes, highlighted by studies of
the S100A10-null mouse. The first is that S100A10 is a
highly inducible plasminogen receptor. S100A10 is not only
regulated by physiologically important signaling molecules
such as thrombin [23], epidermal growth factor [24, 25],
transforming growth factor-α [26], and interferon-γ [27,
28], but also by pathophysiological events such as the
expression of oncogenes that occurs during the process of
tumor development and progression (oncogenesis) [29, 30].
Second, we will summarize our observations that document
that S100A10 is responsible for a significant amount of total
cellular plasmin generation and develop the second theme
that S100A10 plays a key role in physiological processes,
such as fibrinolysis and inflammation. Collectively, we will
showcase the concept that in response to both physiological
and pathophysiological cues, cells utilize S100A10 to regulate
their levels of plasmin proteolytic activity. Our working
model of cellular plasmin regulation by S100A10 is presented
in Figure 1.
2. Historical Perspective
S100A10 was first identified in 1984 during the purification
of a 34 kDa protein substrate of Rous sarcoma virus-
transforming protein tyrosine kinase (pp60v-src) from
chicken embryo fibroblasts [31]. These investigators
observed the presence of a small, 6 kDa protein that was
present at the dye front of Coomassie blue-stained SDS-
polyacrylamide gels. Using preparations from porcine or
bovine epithelial cells, this protein was estimated to have
a molecular mass of 11 kDa and found to share homology
with the glia-specific protein, S-100, and to share about 50%
amino acid homology with S100α [32, 33].
Since its discovery, many proposed intracellular func-
tions have been suggested for S100A10. In the late 1980s
and early 1990s the binding of S100A10 to the protein
annexin A2 was shown to diminish the phosphorylation of
annexin A2, and thereby regulate the association of annexin
A2 with phospholipid membranes [32, 34, 35]. S100A10
was also shown to stimulate annexin A2 translocation to
the cortical cytoskeleton [36] and stimulate the F-actin
bundling activity of annexin A2 during exocytosis [37–39].
Again, in complex with annexin A2, S100A10 was reported
to enhance the annexin A2 stimulation of glial fibrillary
acidic protein (GFAP) polymerization [40] and to play a
role in cytomegalovirus infection [41, 42]. S100A10 was also
shown to have a role in inhibiting inflammation, by targeting
phospholipase A2 [43]. The interaction of S100A10 with
the Bcl-2-associated death promoter (BAD) was shown to
inhibit the proapoptotic activity of the protein [44]. The
interaction of S100A10 with PCTAIRE-1 was reported to
stimulate its protein kinase activity [45, 46]. It was also noted
that S1000A10 was a transglutaminase substrate although the
functional significance of this modification is unclear [47].
The early part of 2000 saw a flurry of publication on
S100A10. In complex with bluetongue virus protein, NS3,
S100A10 was shown to mediate virus release [48]. S100A10
in association with HBV Pol was also reported to inhibit
DNA polymerase activity [49]. The binding of S100A10 to
AHNAK was also reported [50]. During this time, a role for
S100A10 in the regulation of plasmamembrane ion channels
was reported. S100A10 was shown to complex with the two-
pore domain acid-sensitive potassium channel (TASK-1) at
the plasma membrane [51], and interact with the transient
receptor potential cation channel subfamily V member
5/6 (TRPV5/TRPV6) [52], the acid-sensing ion channel 1
(ASIC-1) [53], and with the voltage-gated sodium channel
NaV1.8 [54, 55]. The year 2006 saw reports of the interaction
of the S100A10 protein with the serotonin receptor, 5-HT1B
[56]. Perhaps the most exciting development in the S100A10
field came with the development of the S100A10 gene knock-
out (S100A10-null) mouse. Using a mouse knockout that
entailed a specific S100A10 deletion in nociceptive sensory
neurons, it was reported that S100A10 played a role in
nociception, resulting from decreased sodium current [57].
This study confirmed the role of S100A10 in the regulation
of the expression of Na(V)1.8. This study also reported that
knockout of S100A10 did not aﬀect the protein levels of
its annexin A2 binding partner. A general S100A10 mouse
knockout model also indicated the physiological relevance
of the S100A10–5-HT1B receptor interaction. They found
that these S100A10-null mice are viable but exhibited a
depression-like phenotype with reduced responses to 5-
HT1B agonists, suggesting that S100A10 is not required for
normal mouse development, but that lack of S100A10 causes
a depressive disorder due to its regulation of the 5-HT1B
channels [56].
Since S100A10 can only be purified from tissues as a
complex with annexin A2, our initial studies compared the
structure and function of annexin A2 monomer and the
annexin A2/S100A10 complex isolated from bovine lung. We
called the annexin A2/S100A10 complex, the annexin A2
heterotetramer (abbreviated as AIIt). We reported, in 1998,
that annexin A2/S100A10 complex purified from bovine
lung, regulated plasmin activity by stimulating plasmin
autoproteolysis [58, 59]. We also observed that other purified
annexins, including annexin A2, did not appreciably stimu-
late plasmin autoproteolysis. Later studies would reveal that
the plasmin fragments produced by AIIt-dependent plas-
min autoproteolysis were biologically active antiangiogenic
molecules [60, 61]. An extracellular function for S100A10 as
a plasminogen receptor was initially suggested in the late 90′s
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Figure 1: Regulation of cellular plasmin generation by S100A10. Normal cells and cancer cells utilize the plasminogen receptor, S100A10
(p11), for cell surface plasmin generation. The predominant form of S100A10 at the cell surface is as the heterotetramer, AIIt which consists
of two copies of the annexin A2 (p36) and a S100A10 homodimer. The model shows one-half of this heterotetrameric complex. Annexin
A2 acts as a regulatory subunit which utilizes its phospholipid-binding sites to anchor S100A10 to the cell surface. S100A10 binds tPA and
plasminogen (Pg) at its carboxyl-terminal lysine residue. It is unclear if one molecule of AIIt can bind both tPA and plasminogen at each of
the binding sites on the antiparallel S100A10 monomers or if each molecule of AIIt can only bind two molecules of tPA or two molecules
of plasminogen at the S100A10 monomers. The localization of tPA and plasminogen in close proximity promotes the rapid conversion of
plasminogen to plasmin (Pm) by tPA. Plasmin binds to both annexin A2 and S100A10 at sites distinct from the plasminogen-binding site.
The protease, urokinase-type plasminogen activator (uPA), is secreted from cells in its inactive, zymogen form called pro-uPA. Pro-uPA is
converted to uPA by several proteases including plasmin. The uPA/uPAR complex colocalizes with the AIIt where uPA cleaves the S100A10-
bound plasminogen, generating plasmin. Plasmin cleaves and activates promatrix metalloproteases (MMPs), procathepsin B (pro-CB), and
pro-uPA. Plasmin, MMPs, and cathepsin B degrade many extracellular matrix (ECM) proteins and both release and activate growth factors
from the ECM via proteolysis. Increased cell surface concentration of uPA or pro-uPA (by binding to its receptor, uPAR) and plasmin or
plasminogen (by binding to S100A10) accelerates their reciprocal activation and focuses plasmin proteolytic activity to the cell surface.
by our laboratory. We observed that S100A10 was present
on the surface of cells, predominantly in a complex with
annexin A2, and that this complex dramatically stimulated
tPA-dependent plasmin formation [15]. Using an in vitro
assay with purified components, we showed that the the
annexin A2/S100A10 complex stimulated the rate of activa-
tion of [Glu] plasminogen about 341-fold compared with
an approximate 6-fold stimulation by monomeric annexin
A2. These studies suggested that S100A10 and not annexin
A2 was an important regulator of plasmin generation and
plasmin activity. The cloning and purification of full-length
human recombinant annexin A2 and S100A10 in 1997 [62]
allowed the detailed characterization of the interaction of
tPA and plasminogen with S100A10 complexed with annexin
A2 as well as, for the first time, with the free S100A10
homodimer. We reported that the human recombinant
annexin A2/S100A10 complex stimulated tPA-dependent
plasminogen activation by about 77-fold compared with
about 2- and 46-fold for human recombinant annexin A2
monomer and homodimeric S100A10, respectively [19]. We
also showed that the loss of the carboxyl-terminal lysine
residues of homodimeric S100A10 or S100A10 complexed to
annexin A2 blocked tPA-dependent plasminogen activation
[19, 20]. Finally, we showed that the addition of a peptide
to the S100A10 binding site of annexin A2 (the amino-
terminal 15 amino acids), to the recombinant S100A10
homodimer, increased the rate of tPA-dependent plasmino-
gen activation by two-fold compared with the stimulation by
homodimeric S100A10 alone [19]. The activity of this trun-
cated recombinant complex, formed by the binding of this
peptide to the recombinant S100A10 homodimer (annexin
A2(1−15)/S100A10), was comparable to the activity of the
intact annexin A2(1−338)/S100A10 complex. This indicated
that within the annexin A2/S100A10 complex, S100A10 was
the subunit directly responsible for plasmin generation and
that the interaction of annexin A2 with S100A10 functioned
to stimulate the activity of S100A10. These studies were
extended in 2003 when we used surface plasmon reso-
nance to examine the interaction of tPA and plasminogen
with homodimeric S100A10 and S100A10 complexed with
annexin A2 [63]. We reported that homodimeric S100A10
bound tPA and plasminogen and that S100A10 complexed
with annexin A2 bound plasminogen with higher aﬃnity
than homodimeric S100A10. Since we also observed that
annexin A2 did not bind tPA or plasminogen, we concluded
that the binding of annexin A2 to S100A10 increased the
aﬃnity of S100A10 for plasminogen.
In 2003-2004 we used antisense RNA or small inter-
fering RNA (shRNA) to selectively deplete S100A10 from
cells. These studies established that S100A10 contributed
significantly to the total cellular plasmin generation and
that S100A10-dependent plasmin generation was utilized by
cancer cells to promote invasion and metastasis [64, 65]. In
2010-2011 studies with the S100A10-null mouse contributed
greatly to our understanding of the role of S100A10 as
a plasminogen receptor. We found that mice deficient in
S100A10 had increased fibrin deposition in various tissues
including the lungs, liver, spleen, and kidney. These mice
exhibited impaired fibrinolysis, illustrated by an inability to
clear microclots formed by the snake venom, batroxobin.
These mice also showed decreased angiogenesis, evidenced
by a decreased infiltration of endothelial cell into Matrigel
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plugs [66]. We also demonstrated that cell surface S100A10
played an important role in the migration of macrophages
to the site of inflammation [67]. Our lab group recently
explored the role of S100A10 on the surface of macrophages
and the ability of these cells to enhance tumor growth [68].
Mice deficient in S100A10 grew smaller tumors than their
wild-type counterparts, but injection of macrophages that
express S100A10 into the tumors of the S100A10-null mice
resulted in an increase in tumor growth rate similar to that
of wild-type mice. These studies established that S100A10
was essential and suﬃcient for macrophage migration to
tumor sites, and that the S100A10-dependent migration of
macrophages to the tumor site was a novel rate-limiting step
in tumor progression.
Most recently, two studies have contributed greatly to
our understanding of the regulation of S100A10. In 2011,
Lin’s group demonstrated that the transport of S100A10 to
the extracellular surface requires annexin A2 and is mediated
by the exosomal transport pathway [28]. During this time,
it was also shown that the expression of the protein, DLC1,
resulted in the binding of DLC1 to S100A10 which decreased
the S100A10 levels because DLC1 displaced annexin A2
from S100A10 which resulted in the ubiquitin-dependent
degradation of S100A10 [69]. This result established that a
primary function of annexin A2was to protect S100A10 from
degradation, a property not shared by all S100A10-binding
proteins.
3. S100A10 Structure
The S100 family of proteins are small acidic calcium-binding
proteins of 9–13 kDa that, excluding pseudo genes and fused
S100 proteins, consist of about 20 genes (reviewed in [70–
72]). Sixteen S100 genes are tightly clustered in a region of
the human chromosome 1q21 and are designated as S100A
followed by Arabic numbers (S100A1-S100A16). Another
four S100 genes outside the 1q21 locus carry a single-letter
stem symbol (S100B, S100P, S100Z, and S100G). The S100
proteins belong to a large family of Ca2+-binding proteins
called the EF hand superfamily that includes proteins such
as calmodulin, parvalbumin, troponins, and CaBPs [73]. On
the basis of the parvalbumin structure, Kretsinger identified
the structure responsible for Ca2+ binding and coined the
term for this Ca2+-binding structure as the EF hand motif
[74].
The S100 proteins typically contain two EF hand motifs
(two α-helices linked by a Ca2+-binding loop): an S100-
specific EF hand at the N-terminus and a canonical EF hand
at the C-terminus. In all of the S100 proteins except S100A10,
the EF hands are responsible for Ca2+-binding. These EF
hands are not equivalent as the carboxyl-terminal EF hand
Ca2+-binding loop contains the classical 12-amino-acid Ca2+
binding motif that is common to all EF hand Ca2+-binding
proteins such as parvalbumin and calmodulin. In this motif,
Ca2+-binding occurs via acidic side chains that comprise the
sequence DXDGDGTIXXXE. In contrast, the N-terminal EF
hand motif is a 14-amino-acid Ca2+ binding loop which is
characteristic of all S100 proteins and is referred to as the
S100 specific or pseudo EF domain. This motif binds Ca2+
via backbone carbonyl groups and only by one carboxylate
side group of glutamic acid [75]. Some of the S100 proteins
also bind zinc and copper cations at sites distinct from the
EF hand motifs [76]. In addition to the EF domains, the
S100 proteins also possess a carboxyl-terminal extension.
Some S100 proteins have long and flexible carboxyl-terminal
extensions and this region has been suggested to be required
for a ligand interaction independent of the EF hand. In
general, the carboxyl-terminal extension exhibits the highest
sequence variation and has been suggested to be a major
contributor to the specificity of S100 proteins [77].
Calmodulin was the first multifunctional EF hand con-
taining Ca2+-binding protein that was shown to be highly
conserved and present in all eukaryotes [78]. In contrast, the
S100 protein family has been proposed to have originated
during the Ordovician period, about 460 million years ago,
with the evolution of vertebrates. S100 proteins most likely
originated from a calmodulin-type precursor protein by gene
duplication or exon recombination with subsequent loss
of two of the four EF hands [73, 75, 79]. S100 proteins
have been only isolated from vertebrates, and the analysis
of the available genomes of nonvertebrate eukaryotes such
as nematodes, insects, and protozoa has suggested the
absence of S100-like sequences from these organisms [80].
This suggests that S100 proteins form a phylogenetically
young group among the EF hand proteins. Despite their
phylogenetic short history, the diversification in the S100
family is so extensive, that the S100 proteins actually form
the largest subgroup among the EF hand proteins. The
members of the S100 protein family are multifunctional
signaling proteins that are involved in the regulation of
diverse cellular processes such as transcription, secretion,
contraction, motility, cell growth, diﬀerentiation, and cell
cycle progression. Diseases associated with altered expression
levels of S100 proteins include diseases of the heart, diseases
of the central nervous system, inflammatory disorders, and
cancer progression (reviewed in [77]). The diversity of
binding partners for the S100 proteins is illustrated by
the reports that S100 proteins are involved in at least 68
interactions with non-S100 targets (IntAct database of binary
interactions (http://www.ebi.ac.uk/intact/). In fact, one S100
family member, S100A8, has been reported to interact with
as many as 27 partners [81]. One of the possible explanations
for the functional versatility of S100 proteins is the recent
suggestion that most of the S100 proteins are intrinsic
disordered proteins and as a result of structural plasticity,
these proteins can interact with diﬀerent targets and in some
cases adopt diﬀerent conformations, depending upon the
specific ligand bound [82].
The majority of S100 proteins form symmetric nonco-
valent homodimers, a feature that is unique to the EF hand
family. The dimer is formed by the interaction of helices I and
IV of each monomer thus forming an antiparallel structure.
Although infrequent, heterodimers have been shown to
form between certain S100 proteins, such as that formed
between S100A8 and S100A9 [83]. The only monomeric
S100 family member is S100G (calbindin-D9k). Upon Ca2+
binding, all S100 proteins except S100A13 [84] undergo a
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conformational change that results in a large reorientation
of helix III whereas helix IV and the N-terminal EF hand
show only minor structural changes. Specifically, the Ca2+-
binding event results in the N-terminus of helix III shifting
by about 40 degrees relative to helix IV which results in
helix III adopting a position that is nearly perpendicular
to helix IV. As a consequence five hydrophobic residues on
helix IV, as well as on two hydrophobic residues in helix I
and three hydrophobic residues in the hinge region which
was previously buried in the Ca2+-free state, are exposed and
form the site utilized for ligand interactions (reviewed in
[72]).
S100A10 is unique among S100 family members in that
its EF hands cannot bind Ca2+. Each S100A10 monomer
is composed of four α-helical domains of variable length
referred to as H-I (Q3-A19), H-II (K27-K36), H-III (A50-
L58), and H-IV (F68-H89) (Figure 2). Separating H-I and
H-II helical regions is a loop which along with contributions
from H-I and H-II forms a Ca2+-binding loop (L1; A19-L30)
and the H-I-L1-H-II domain forms the S100-specific, EF-1
domain. The H-III and H-IV domains are separated by a
second loop (L2; D59-S70) and the H-III-L2-H-IV domain
forms the canonical EF hand motif, EF-2. The EF-1 and
EF-2 domains are connected by a flexible linker or hinge
region (HR1: P39-N44). S100A10 has three deletions in L1
thus rendering this domain incapable of binding Ca2+. Two
substitutions involving a glutamic and asparagine residue in
EF-2 of S100A10 also render this domain incapable of bind-
ing Ca2+. Although the EF hands of S100A10 are unable to
bind Ca2+, the conformation of S100A10 resembles the Ca2+
“on” state of other S100 proteins, therefore the mutations in
S100A10 result in a constitutively active conformation [85].
Thus the interaction of S100A10 with its best characterized
ligand, annexin A2, is Ca2+ independent [62].
X-ray crystallographic analysis and site-directed mutage-
nesis studies have revealed that a hydrophobic cleft formed by
the hingeHR1 and helix H-IV of onemonomer and helix H-I
of the other monomer of S100A10 form the binding site with
the amino-terminal region of annexin A2 [85–88]. These
points of interaction between annexin A2 and S100A10 are
quite extensive. Four hydrophobic amino acids of the amino
terminus of annexin A2 (V3, I6, L7, and L10) form seven
points of contact with helix H-I of one monomer, two
points of contact with the hinge region, and nine points of
contact with helix H-IV of the other monomer, for a total of
nineteen points of contact between annexin A2 and S100A10
(reviewed in [71]). In addition, T2 of S100A10 interacts with
E9 and F13 of H-I (A. Rety, personal communication). Site-
directed mutagenesis experiments have identified important
interactions between annexin A2 and Y85 and F86 of helix
H-IV of one S100A10 monomer and E5 and E9 of helix H-
I of the other monomer [88]. The interaction of S100A10
with annexin A2 produces a heterotetrameric complex that
is referred to as AIIt. This interaction aﬀects the structure of
both molecules. Annexin A2 aggregates chromaﬃn granules
with a Kd(Ca2+) in the millimolar range. Partial proteolysis
results in the removal of the first 27 or 43 residues of the
amino terminus and reduces the Kd(Ca2+) for chromaﬃn
granule aggregation about 10- or 50-fold, respectively. The
binding of the S100A10 to the annexin A2 also reduces
the Kd(Ca2+) of chromaﬃn granule about aggregation to
about 2 μM. This suggests that the amino-terminus exerts
an inhibitory constraint on the interaction of annexin A2
with its biological targets whereas the binding of the S100A10
reverses this inhibitory restraint (reviewed in [39]).
As discussed, S100 proteins interact with a large variety
of target molecules and S100A10 is certainly no exception
(reviewed in [12, 21, 22]). S100A10 (in association with
annexin A2 as the heterotetrameric complex, AIIt) partici-
pates in the recruitment and/or function of Na+, K+, Ca2+,
and Cl−channels and serotonin receptors ([51, 52, 54, 56,
89]. Other proteins have been reported to bind S100A10,
including phospholipase A2 [43], cathepsin B [90, 91], BAD
[44], PCTAIRE1 [46], DLC1 [69], and AHNAK [50]. The
site of interaction of S100A10 with the bluetongue virus
protein, NS3 (M-L-S-G-L-I-Q-R-F-E-E-E) [48], TASK-1 (G-
F-R-N-V-Y-A-E-V-L-H-F) [51], AHNAK (G-K-V-T-F-P-K-
M-K-I-P-K-F-T-F-S-G-R-E-L) [92], and DLC1 (S-T-F-N-N-
V-V-E-Q-N-F-K) [69] has been reported. The binding site
between S100A10 and annexin A2 (T-V-H-E-I-L-C-K-L-C)
forms the general interaction motif (X-O-O-X-X-O-O-X-
O) where X refers to hydrophobic residues and O is any
other residue [93]. The binding region of AHNAK which
binds to both annexin A2 and S100A10 within the AIIt
complex, only partially possesses this motif. However, both
NS3 and TASK-1 show similarities to this motif and both
of these proteins appear to compete with annexin A2 for
S100A10. Importantly, the amino-terminal region of annexin
A1, (AMVSEFLKQAWFI) does not interact with S100A10
but possesses a similar motif.
The competition of ligands for the annexin A2 binding
site on S100A10 has important consequences for the stability
of S100A10. The detailed study of the interaction of S100A10
with DLC1 established that annexin A2 serves to protect
S100A10 from ubiquitin-mediated degradation and ligands
that displace annexin A2 from S100A10 will cause the rapid
degradation of S100A10. It has been suggested that many
of the binding partners of S100A10 may utilize the protein
as a mechanism of cotransport to the plasma membrane;
however if the binding of these ligands results in the
disassociation of annexin A2 then rapid degradation of the
S100A10-ligand complex would be expected. Therefore only
ligands that bind to both subunits and/or do not dissociate
annexin A2 from S100A10 would benefit from binding to
S100A10. It was also interesting that overexpression of DLC1
which resulted in the depletion of S100A10 levels resulted in
the inhibition of plasmin generation and invasion of aggres-
sive lung cancer cells [69]. This study therefore confirmed
the importance of S100A10 as a plasminogen receptor and
regulator of cellular plasmin generation [29, 64–68]. This
study also provided important structural information on
the ligand binding motif between S100A10 and DLC1 and
annexin A2. A comparison of the binding regions of annexin
A2 (S-T-V-H-E-I-L-C-K-L-S) with DLC1 (S-T-F-N-N-V-V-
E-Q-N-F-K) suggests that a minimal binding motif may be
T-X-O-O-X-X-O) in which L10 of annexin A2 does not play
an important role in binding to S100A10. Consistent with
this suggestion is that the interaction of L10 forms only weak
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Figure 2: Structure of S100A10. A cartoon of the association of S100A10 with its two primary ligands, annexin A2 and plasminogen, is
presented in A. The figure illustrates the structure of S100A10 and the association of S100A10 with the amino-terminus of annexin A2 and
with plasminogen. Each S100A10 monomer is composed of four α-helical domains H-I, H-II, H-III, and H-IV. Separating H-I and H-II
helical regions is a loop, L1. The H-III and H-IV are separated by a second loop (L2). The H-II and H-III are connected by a flexible linker
or hinge region (HR1). The points of interaction between the amino-terminus of annexin A2 and S100A10 are quite extensive and four
hydrophobic amino acids of the amino terminus of annexin A2 (V3, I6, L7, and L10) form seven points of contact with helix H-I of one
monomer, two points of contact with the hinge region, and nine points of contact with helix H-IV of the other monomer for a total of
nineteen points of contact with S100A10. Shown also are the helical wheel projections for the S100A10-binding site for B, annexin A2; C,
NS3; D, DLC1; E, TASK-1. The S100A10-binding region of these ligands consists of an amphipathic α-helix in which hydrophobic residues
form a binding site on one side of the helix. The program for helical wheel projections was obtained from http://www.kael.net/helical.htm.
van der Waals interactions with the residues of helix IV (S.
Rety, personal communication).
Previous studies have shown that S100A10 binds both
tPA and plasminogen through its carboxyl-terminal lysine
[19]. Thus a binding site for tPA and plasminogen is present
on each S100A10monomer which contrasts with the annexin
A2 binding site for S100A10 that requires the participation
of both S100A10monomers. Although the carboxyl-terminal
extension of S100A10 plays an important role in the function
of the protein, it is unclear if other amino acid residues
other than the carboxyl-terminal lysine also participate in
tPA or plasminogen binding. However, since removal of
the carboxyl-terminal lysines of either S100A10 alone or
S100A10 complexed with annexin A2 completely inhibited
tPA and plasminogen binding, it is likely that the carboxyl-
terminal lysine of S100A10 plays a key role in tPA and plas-
minogen binding [15, 20, 63]. As had been shown for many
plasminogen-binding proteins, the carboxyl-terminal lysine
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Figure 3: Schematic representation of the human S100A10 promoter. Transcription factor-binding sites are marked with color boxes.
forms a binding site for the lysine binding domains (kringles)
of both tissue plasminogen activator (tPA) and plasminogen
(reviewed in [12, 13, 18, 94]). Figure 8 presents the amino
acid sequence of several well-established plasminogen recep-
tors. Although these receptors all possess carboxyl-terminal
lysines it was interesting to note that several of the receptors
also displayed a basic amino acid five residues distant from
the carboxyl-terminal lysine, at a position corresponding
to K91 in S100A10, suggesting that this residue may also
play an important role in plasminogen receptors. Analysis
of the phylogenetic distribution of S100A10 reveals that
the carboxyl-terminal lysine is conserved across all species
from human to fish (Figure 9). Only Xenopus S100A10 does
not possess a carboxyl-terminal lysine. Interestingly, K91 (in
the human S100A10 sequence) is absolutely conserved in
all species examined. Whether this residue plays a role in
maintaining the orientation of the carboxyl-terminal residue
or directly participates in ligand binding is unclear. It is
not unreasonable to suspect that K91 may influence the
aﬃnity of interaction between plasminogen and S100A10.
The binding of annexin A2 to S100A10 increases the aﬃnity
of plasminogen binding to S100A10 by about ten fold,
suggesting that the plasminogen binding to the carboxyl-
terminal lysine of S100A10 is influenced by the conformation
of S100A10 [63].
The other S100 family members that possess carboxyl-
terminal lysines include S100A4, S100A5, S100A13, S100P,
and S100Z. Interestingly, of these S100 proteins, plasmino-
gen binding has only been reported for S100A4 [95]. As
discussed, S100A10 is present in mammals, birds, reptiles,
amphibians, and fish, but not in insects, nematodes, pro-
tozoa, fungi, or plants (Figure 9). Similarly, plasminogen,
one of the established ligands of S100A10, is present in
vertebrates including fish [96]. In contrast, S100A2, S100A7,
S100A12, S100Z, and S100P are present in humans but not
in mouse and rat [73]. The expression of S100A2, S100A3,
S100A4, S100A5, and S100A6 is restricted to mammals and
is absent in birds and fish [80]. Therefore, the presence of
a carboxyl-terminal lysine has been highly conserved in the
structure of S100A10 and appears to parallel the phylogenetic
distribution of its ligand, plasminogen. Similarly the pres-
ence of the S100A10-annexin A2 complex in the swamp eel is
consistent with the phylogenetic conservation of the annexin
A2 binding site on S100A10 [97].
4. Regulation
S100A10 is expressed fairly ubiquitously in most cells and
tissues yet its promoter region lacks a TATA box. Several
binding motifs for various transcription factors have been
identified within the promoter region of S100A10, such as
binding sites for the transcription factor Sp1 [98]. Interferon
(IFN)-γ has been shown to induce S100A10 expression in
epithelial cell lines through the transcription factor STAT1
[27] (Figure 3). STAT1-induced S100A10 expression was
dependent on the presence of GAS sites in the S100A10
promoter region. The promoter region for S100A10 also
contains glucocorticoid response elements (GREs) and glu-
cocorticoid stimulation has been demonstrated to induce
S100A10 expression [99–101]. S100A10 expression may
additionally be induced by transforming growth factor-β
[26], gonadotrophin, epidermal growth factor, basic fibrob-
last growth factor, and interleukin 1β [24, 25, 102]. Decreases
in S100A10 expression have been associated with increased
risk of depression. Recently, S100A10 promoter hyperme-
thylation has been demonstrated in studies using a rodent
model of depression and hypermethylation of the S100A10
promoter region was reduced following administration of
antidepressants, suggesting potential epigenetic regulation of
S100A10 expression [103].
It was initially observed that depletion of annexin A2
resulted in a concomitant loss of cellular S100A10 and from
this study it was inferred that the S100A10 homodimer was
unstable in the absence of annexin A2 [104]. Subsequently,
it was suggested that S100A10 was rapidly degraded by a
proteosomal degradation mechanism [105]. Finally, it was
observed that DLC1 decreased the cellular levels of S100A10
by binding to S100A10 which resulted in the displacement of
annexin A2 from S100A10. Although annexin A2 and DLC1
bound to the similar site on S100A10, the binding of DLC1 to
S100A10 did not protect S100A10 from ubiquitin-mediated
degradation. Thus, the displacement of annexin A2 by DLC1
resulted in the ubiquitin-mediated degradation of S100A10
[69]. Conceptually, these experiments established the impor-
tant regulatory role of annexin A2 in protecting S100A10
from ubiquitin-mediated degradation and identified a new
mechanism of regulation of S100A10 by the expression
of proteins such as DLC1 that displace annexin A2 from
S100A10 and in doing so target S100A10 for destruction.
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Figure 4: S100A10 and annexin A2 protein levels in tissues from S100A10−/− mice. Annexin A2 and S100A10 protein levels were analyzed
by Western blot in tissues isolated from wild-type (WT) and S100A10−/− mice. Annexin A2 protein levels decreased in lung (a), kidney (c),
and spleen (d), were not detectable in liver (b) and were unaltered in the small intestine (e). As expected, S100A10 protein levels were not
detected in tissues isolated from S100A10−/− mice.
Other groups have demonstrated that annexin A2 may also
stabilize S100A10 mRNA levels as loss of annexin A2 resulted
in decreased S100A10 mRNA levels in MDA-MB-435 cells
[106], melanocytes, and L5178Y murine lymphoma cells
[107]. We have also detected S100A10 protein in murine liver
in the absence of measurable annexin A2 (Figure 4). The
mechanisms by which S100A10 is expressed and regulated
posttranslationally by annexin A2 therefore appear to be cell-
type dependent.
As discussed, S100A10 is present on the extracellular
cell surface as a complex with annexin A2, called AIIt
[15]. The annexin A2 subunits of AIIt serve to anchor
AIIt to the plasma membrane in a Ca2+-dependent fashion
[108–110]. Several groups have reported that annexin A2
is required to transport S100A10 to the cell surface [111–
113]. Annexin A2, however, lacks a signal peptide which
suggests that the transport to the cell surface occurs by
an unconventional secretion pathway [114]. Others have
shown that the transport of S100A10 to the cell surface
requires the phosphorylation of annexin A2 [111–113].More
recently, Fang et al. described a mechanism by which IFN-
γ stimulated expression of S100A10 results in increased
S100A10 levels on the cell surface. They demonstrated that
S100A10 transport to the cell surface is dependent on
annexin A2 and utilizes the exosomal secretion pathway [28].
A model for the transport of S100A10 to the cell surface is
presented in Figure 5.
5. Cellular and Tissue Distribution
S100A10 is present in the cell primarily with annexin A2 as
part of the annexin A2/S100A10 heterotetrameric complex.
This complex, called AIIt, is formed by the binding of
two molecules of annexin A2 to the S100A10 homodimer.
Annexin A2, which binds cellular membranes, serves as
the membrane anchor for S100A10. Intracellular S100A10
participates in the traﬃcking of several plasma membrane
proteins, including the 5-HT1B receptor [56], TRPV5 and
TRPV6 [52, 89], TASK-1 [51, 115], and Na(V)1.8 [54].
S100A10 present on the cell surface membrane as a complex
with annexin A2 is a prominent plasminogen receptor
and participates in tPA- and uPA-dependent plasminogen
activation at the cell surface [15, 29, 64–67].
Expression of S100A10 has been reported in a wide
range of cell types and tissues. The expression of S100A10
protein is highest in lung, kidney, and intestine. S100A10
has also been observed in various cell types, including
endothelial cells [66, 111], macrophages [67, 68, 116, 117],
fibroblasts [37], epithelial cells [27, 89], and various cancer
cell lines [29, 64, 65, 69, 106, 107, 118–121]. S100A10 is
not detected in erythrocytes [37] and relatively low levels of
S100A10 are found in the liver [122]. Our laboratory has
shown the expression of S100A10 protein in murine lung,
liver, kidney, spleen, and intestine (Figure 4). Interestingly,
S100A10 appears to regulate annexin A2 protein levels in a
tissue-specific fashion. We investigated annexin A2 protein
and mRNA levels in tissues isolated from the S100A10-null
mouse (Figure 6) and observed that the loss of S100A10
aﬀected annexin A2 levels in a tissue specific fashion. While
loss of S100A10 did not aﬀect annexin A2 levels in the
intestine, it resulted in decreased annexin A2 levels in the
lung, liver, spleen and kidney. On the other hand, annexin
A2 mRNA levels were not altered in any of the S100A10-null
tissues (Figure 6). S100A10 therefore appears to contribute
to annexin A2 protein stability in a tissue specific fashion.
6. Function(s)
6.1. Role As a Plasminogen Receptor. In order for a protein
to be considered a plasminogen regulatory protein, several
critical must be met. First, the putative plasminogen reg-
ulatory protein must bind plasminogen. Surface plasmon
resonance studies have demonstrated that S100A10 binds
plasminogen, (Kd of 1.81 μM), plasmin (Kd of 0.36 μM),
and tPA (Kd of 0.45 μM). Furthermore, S100A10 possesses
the requisite carboxy-terminal lysine that has been shown
to be essential for plasmin activation at the cell surface.
Removal of the carboxy-terminal lysines (carboxy-terminus
of S100A10- [85]-Y-F-V-V-H-M-K-Q-K-G-K-K [96]) atten-
uates plasminogen and tPA binding [63]. Second, binding
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Figure 5: Regulation of the expression of extracellular S100A10. Many physiological agents (EGF, interferon-γ, transforming growth factor-
α) and pathophysiological agents (PML-RARα and KRas oncogenes) stimulate the upregulation of S100A10 protein levels. Annexin A2 is
thought to play two important roles in the export of S100A10. First, the association of annexin A2 with S100A10 protects S100A10 from
ubiquitin-mediated proteasomal degradation as S100A10 is rapidly degraded in the absence of annexin A2. Secondly, the binding of annexin
A2 with S100A10 is thought to promote the capture of the complex by the exosomes. Exosomes are small vesicles, approximately 30–100 nM
in diameter, that are formed by the inward budding of large intracellular compartments called multivesicular endosomes (MVE). Proteins
and RNA that are present in the cytoplasm are trapped within the lumen of the exosomes during this inward budding process and proteins
that associate with the MVE lumenal membrane during MVE budding are localized to the outer surface of the exosomes. The exosomes,
sequestered as intact vesicles within the MVE, are released from cells when the membrane of the MVE fuses with the plasma membrane.
The association of annexin A2 with exosomes has been reported but it is unclear at this time if the S100A10/annexin A2 complex is present
on the surface or in the lumen of the exosomes. In our speculative model, we show that S100A10 protein that is synthesized in response to
oncogenic agents such as oncogenic Ras or the PML-RAR oncogene forms a complex with annexin A2. The S100A10/annexin A2 complex is
then sequestered with the lumen of the exosomes during the inward budding of the MVE (A). These MVEs fuse with the plasma membrane
resulting in the release of the exosomes into the extracellular space. These exosomes rupture and release the S100A10/annexin A2 complex
from their lumenwhich then allows the association of the complex with the plasmamembrane. Alternately, the S100A10/annexin A2 complex
may be present on the lumenal surface of theMVE (B). The inward budding of theMVE results in the association of the S100A10/annexin A2
complex with the outer surface of the newly formed exosomes. The exosomes released by the fusion of the MVE with the plasma membrane
fuse with the plasma membrane resulting in the incorporation of the S100A10/annexin A2 complex at the plasma membrane.
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Figure 7: Role of S100A10 in Tumor Formation. HT1080 fibrosarcoma cells (106 cells) were injected intradermally into SCID mice and
dissected and weighed after 20 days. Thirteen mice were used in each group. The dissected-20 day tumors were photographed. 7/13 of
mice injected with S100A10 antisense HT1080 cells developed tumors compared to 100% tumor development for the WT HT1080 cells.
Furthermore, the tumors grown by the S100A10-depleted HT1080 cells were much smaller. The data shows that the loss of S100A10 from
the cancer cell surface and the resultant loss of protease activity inhibited tumor growth.
of plasminogen to the candidate regulatory protein must
convert plasminogen into the open, activation-susceptible
conformation. Studies using plasminogen that was FITC
labeled at its active site showed that addition of either AIIt
or S100A10 alone, but not annexin A2 alone, resulted in
quenching of the fluorescence of plasminogen, meaning
that S100A10 promoted an open, activatable conformation
of plasminogen [19]. Third, the plasminogen receptor
should be inactivated by removal of its carboxyl-terminal
lysine. S100A10 is a high aﬃnity substrate for several
carboxypeptidases, which have been shown to block cellular
plasminogen activation by cleaving carboxy-terminal lysines
[7]. Our laboratory has demonstrated that carboxypeptidase
B (CpB) ablates enhancement of plasminogen activation
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by homodimeric S100A10 or by the S100A10/annexin A2
complex through removal of carboxy-terminal lysines of
S100A10 [20]. Fourth, binding of plasminogen regulatory
proteins to plasmin or plasminogen activators must protect
these enzymes from inactivation by their inhibitors. S100A10
has been shown to protect tPA and plasmin from PAI-1 and
alpha2-antiplasmin, respectively [15]. Fifth, although not a
criterion for a plasminogen receptor per se, it is expected
that in order for a plasminogen receptor to eﬃciently convert
plasminogen to plasmin it should bind to or colocalize with
plasminogen activators. S100A10 binds directly to tPA and
colocalizes with uPAR on the cell surface. Studies from
our laboratory have demonstrated the presence of uPAR in
S100A10 precipitates and colocalization has been observed
by immunofluorescence microscopy [15, 64, 65]. Sixth,
depletion of the plasminogen receptor from the cell surface
should result in a loss in cellular plasmin generation. The loss
of S100A10 from the cell surface results in a loss of cellular
plasmin generation. In vitro studies have demonstrated
that when HT1080 fibrosarcoma cells were transfected with
antisense S100A10, resulting in depletion of S100A10 but
not annexin A2, plasmin production was reduced by 95%
and extracellular matrix hydrolysis was decreased by almost
70% in comparison to the vector controls. Furthermore,
tumor formation in SCID mice was dramatically reduced in
S100A10-antisense-transfected cells compared to the vector
control (Figure 7). Taken together, this evidence supports a
key role for S100A10 in plasmin regulation and in the process
of oncogenesis.
6.2. S100A10 in Fibrinolysis. Increasing evidence has shown
that the plasminogen receptor, S100A10, is a main regulator
of plasmin activity at the surface of endothelial cells playing
a main role in vascular fibrinolysis. Our laboratory recently
used a human microvascular endothelial cell line, called
telomerase immortalized microvascular endothelial (TIME)
cells [123], to investigate the role of S100A10 in fibrinolysis
[66]. We used an shRNA system to deplete these cells of
S100A10 and observed a significant impairment in both
plasminogen binding (50%) and plasmin generation (60%)
even though the cell surface levels of its binding partner
annexin A2 were identical in the S100A10-depleted cells
compared to the control cells expressing a scramble shRNA
[66]. On the other hand, annexin A2-depleted TIME cells
showed similar losses in plasminogen binding and plasmin
generation as the S100A10-depleted TIME cells [66]. Taking
into consideration that the annexin A2-depleted TIME cells
were also depleted of S100A10, we concluded that the loss of
cell surface annexin A2 did not aﬀect plasminogen binding
or plasmin generation in these endothelial cells. In view of
these results we have proposed that annexin A2 functions to
stabilize S100A10 protein levels and to localize S100A10 to
the cell surface of endothelial cells, while S100A10 is directly
responsible for plasminogen binding and plasmin generation
by endothelial cells [12].
The role of S100A10 in fibrinolysis in vivo has been
recently established using the S100A10-null mouse model.
These studies showed an enhanced accumulation of fibrin
in the S100A10-null mice tissues compared to wild-type
mice litter mates. These studies initially demonstrated that
the enhanced fibrin deposition observed in the S100A10-
null mice tissues was not due to increased coagulation,
since PT (prothrombin time) and aPTT (activated partial
thromboplastin time) assays, which directly measure coag-
ulation, were identical for both the WT and the S100A10-
null mice [66]. In order to directly investigate fibrinolysis
in the S100A10-null mice, we used a novel approach which
involved the injection of the snake poison, batroxobin, in
S100A10-null and WT mice. Batroxobin is a thrombin-
like enzyme that rapidly cleaves fibrinogen resulting in the
production of fibrin microclots which are removed from
the vasculature through the process of fibrinolysis. We
then compared the ability of these mice to dissolve the
batroxobin-induced blood clots. This experiment showed
that the S100A10-null mice have significantly lower rates of
fibrinolysis of the batroxobin-induced blood clots in vivo
compared to theWTmice [66]. Finally, a tail clip experiment
showed that mice lacking S100A10 have an approximately
4-fold reduction in the time required for the cessation of
bleeding compared to the WT mice. This is most likely
due to decreased fibrinolysis of the tail clip-induced blood
clot by the S100-null mice. Therefore, a central defect in
the S100A10-null mice involves plasmin generation by the
endothelium. These studies taken together establish that
S100A10 plays a major role in fibrinolysis in vivo.
To investigate if S100A10 plays a significant role in
angiogenesis in vivo, we used a well-established method
where Matrigel (which mimics the extracellular matrix)
is injected in mice allowing for the measurement of the
angiogenic response towards a growth factor stimulus in vivo
[66]. This study showed a defective vascularization of the
Matrigel plugs in the S100A10-null mice compared to the
WT mice, establishing that S100A10 plays an important role
in angiogenesis in vivo. These results were further supported
by another experiment that showed that S100A10-depleted
endothelial cells have a significantly decreased ability to
migrate through Matrigel barriers. In conclusion, the studies
performed using the S100A10-null mouse model clearly
established an important role for S100A10 as a positive
regulator of fibrinolysis and angiogenesis.
6.3. S100A10 in Signalling. S100A10, as part of AIIt, has also
been shown to function as a receptor in plasmin-induced
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Figure 9: S100A10 phylogeny.
signaling in monocytes [124] and macrophages [125]. After
having demonstrated that monocytes show a chemotactic
response to plasmin that is dependent on S100A10 and
annexin A2 [124], the Simmet group showed that plasmin,
through S100A10 and annexin A2, activates macrophages
by a mechanism involving stimulation of the Janus kinase
JAK1/TYK2 signaling pathway. JAK1/TYK2 leads to STAT3
activation, Akt dependent NF-κB activation and phosphory-
lation of extracellular signal-regulated kinase 1/2 (ERK1/2)
and mitogen-activated kinase, p38. Plasmin also triggered
nuclear translocation of STAT3 and p65 transcription factors
and the induction of the proinflammatory cytokines tumor
necrosis factor-α and interleukin-6. The Simmet group has
proposed a mechanism by which plasmin cleaves annexin
A2 at lysine 27 (K27), resulting in disruption of AIIt at the
cell surface and transduction of a signaling cascade inside the
cell. Further work needs to be performed to identify a more
complete mechanism by which AIIt serves as a signaling
receptor and transduces this signal into the cell.
7. Role of S100A10 in Disease
7.1. S100A10 in Depression. S100A10 is expressed in several
regions of the brain and through its interactions with 5-
HT1B receptors and NaV1.8/ASIC-1 channels, the involve-
ment of S100A10 in the regulation of depression-like states
and nociception has been thoroughly examined [53, 54, 56].
5-HT1B receptors modulate serotonin neurotransmission by
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acting as both autoreceptors on serotonin-containing neu-
rons originating from the raphe nuclei and heteroreceptors
on several neurons that do not contain serotonin [126, 127].
5-HT1B receptors have been demonstrated to play a role in
the pathophysiology of multiple mental disorders, including
depression [128, 129].
S100A10 levels are decreased in a mouse model of
depression and in brain tissue from unipolar depressed
patients. The S100A10-null mice demonstrate significantly
reduced responsiveness to stimulation of 5-HT1B receptors
in biochemical, electrophysiological, and behavioural tests
thus providing strong evidence to suggest that the interaction
between S100A10 and 5-HT1B receptors plays a role in the
pathophysiology of depression-like states. Further evidence
suggests that decreased levels of S100A10 correlate with
greater susceptibility to depression [56]. The S100A10-null
mouse demonstrate a reduced number of 5-HT1B receptor
ligands which are likely mediated by multiple mechanisms,
such as altered recruitment of the receptors to the cell mem-
brane or disturbed endosomal recycling and/or degradation
of the receptor. In contrast, overexpression of S100A10 leads
to an increase in the number of 5-HT1B receptors at the cell
surface and recapitulates certain behaviors seen after antide-
pressant treatment in mice [56]. Similarly, administration of
antidepressants increases S100A10 expression in the brain
[130].
In addition to results seen at the cellular level, the
S100A10-null mouse exhibits a depressive-like phenotype in
which they display a decreased thigmotaxis and increased
immobility in tail suspension tests in response to imipramine
[56]. Taken together, these results show that S100A10 plays
an important role in the dynamic modulation of 5-HT1B
receptor function and that decreased expression of S100A10
leads to a depressive-like state.
7.2. S100A10 in Inflammation
7.2.1. S100A10 Regulates Plasminogen-Dependent Macro-
phage Invasion. It has been shown that the cell surface gen-
eration of plasmin is required for macrophage recruitment
to a site of inflammation and that macrophage recruitment
is mediated in part through the plasmin-dependent acti-
vation of MMP-9 [131]. Therefore, macrophage-generated
plasmin plays two roles in invasion; it directly hydrolyzes
extracellular matrix (ECM) proteins and it activates MMP-
9, thus promoting further ECM degradation. Analysis of
the plasminogen receptors on the surface of macrophages
has identified α-enolase, histone H2B, and Plg-RKT as plas-
minogen receptors that participate in macrophage invasion
[7, 132–134]. Recent studies performed by our labora-
tory investigated the mechanism of plasminogen-dependent
inflammatory cell recruitment in vivo using two diﬀerent
methodologies: the thioglycollate-induced peritonitis and
the Matrigel plug assay [67]. We observed that in response
to thioglycollate-induced peritonitis, macrophage migration
through the peritoneal membrane into the peritoneal cavity
of the S100A10-null mouse was reduced by about 53%.
Our results with the Matrigel plug assay demonstrated
that S100A10-null macrophages had a limited capability to
infiltrate into the Matrigel plug in vivo. Analysis of the
mechanism of macrophage migration through the Matrigel
suggested that S100A10-null macrophages have a reduced
capacity to generate plasmin and activate MMP-9. Therefore,
the simplest explanation to our results is that S100A10 and
other carboxyl-terminal plasminogen receptors contribute
to macrophage plasmin generation that is utilized for ECM
hydrolysis and MMP-9 activation. Of note was our obser-
vation that neutrophil recruitment to the peritoneal cavity
in response to a thioglycollate-dependent inflammatory
stimulus was also regulated by S100A10. It has been reported
that neutrophil recruitment in plasminogen-null mice is
identical to that of wild-type mice [135] suggesting that
plasmin does not play a role in neutrophil recruitment in
the thioglycollate model. We are currently investigating the
possibility that S100A10 may regulate proteases other than
plasmin on the surface of the neutrophil. For example, it
has been reported that S100A10 regulates the activation of
cathepsin B on the surface of certain cancer cells [90].
Previous studies have established the presence of
S100A10 and its binding partner, annexin A2, on the surface
of murine macrophages [136]. These studies showed that
knockdown of annexin A2 resulted in decreased plasmin
generation, matrix remodeling, and a dramatic loss in
directed migration [137]. However, since annexin A2 knock-
down results in concomitant loss of S100A10, it is diﬃcult
to attribute these eﬀects to either annexin A2 or S100A10.
Annexin A2 levels were reduced in macrophages isolated
from S100A10-null mice, making it unclear if the reduced
macrophage migration in response to thioglycollate-induced
peritonitis was due to the loss of S100A10 or annexin A2 or
both. Elucidating the role that annexin A2 plays in invasion
is complicated by the reports from three laboratories that
intact annexin A2 does not bind plasminogen [63, 133,
138]. Since annexin A2-dependent plasmin generation is
blocked by the lysine analog ε-amino caproic acid or by
treatment of annexin A2 by carboxypeptidase-B [138], it
has been proposed that annexin A2 binds plasminogen
upon proteolytic cleavage of the protein and exposure of
a new carboxyl-terminal lysine [138]. Further proof that
plasminogen binding to annexin A2 requires “activation”
by a carboxyl-terminal cleavage event was provided by
the report that the K307T mutant annexin A2 transfected
into HEK 293 cells failed to bind plasminogen while a
change of a lysine proximal to this site (K328I) bound
plasminogen with similar aﬃnity to the wild type [139]. The
proteinase that has been proposed to cleave annexin A2 has
not been identified but plasmin has been ruled out [139].
We addressed the issue of whether annexin A2 processing
occurred in migrating macrophages in vivo by examining
the molecular mass of cell surface annexin A2 by SDS-PAGE
[67]. The macrophages used in this study were isolated from
the peritoneal cavity of thioglycollate-stimulated mice. We
have recently shown that the loss of the carboxyl-terminal
29 amino acid of annexin A2 (Ser1-Asp338) generates
a truncated form of annexin A2 (Ser1-Lys307), that is
easily detected on SDS-PAGE [14]. However, macrophage
cell surface annexin A2 is similar in molecular mass to
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unproteolyzed annexin A2. Since the macrophages isolated
for these studies were macrophages that had migrated
through the extracellular matrix into the peritoneal cavity
and were therefore proteolytically active, this result suggests
that macrophage cell surface annexin A2 is not cleaved
and therefore does not participate in plasminogen binding,
plasmin generation, or macrophage invasion. Similarly, it has
been reported that annexin A2 is not proteolyzed during
active plasmin generation by HT1080 cells [64]. It was also
interesting that S100A10 and annexin A2 protein levels were
higher in thioglycollate-stimulated peritoneal macrophages
compared to resident peritoneal macrophages, suggesting
that macrophages upregulate S100A10 after activation by
inflammatory mediators.
Our observation that annexin A2 levels were lower in
macrophages isolated from S100A10-null mice compared
to WT mice was unexpected. RT-PCR analysis suggested
that the annexin A2 mRNA levels were similar in these
macrophages [67]. S100A10 has been shown to be ubiqui-
tinated [105, 140] and rapidly degraded by the proteasome.
The binding of S100A10 to annexin A2 protects S100A10
from ubiquitination and proteasomal degradation. In con-
trast, although annexin A2 is ubiquitinated, ubiquitination
does not activate the proteasomal degradation of the protein
[141]. We have also observed that the proteasomal inhibitor,
MG-132, does not aﬀect the annexin A2 levels thereby
eliminating proteasomal degradation as a possible regulatory
mechanism for annexin A2 [29]. However, it is known that
annexin A2 is mainly cytosolic whereas the annexin A2-
S100A10 complex is associated with the cytoskeleton [39,
142]. Since the turnover of cytoskeleton-bound annexin A2
(t1/2 = 40 − 50 h) is three to four times slower than for the
cytoplasmic annexin A2 (t1/2 = 15 h) [37], it is possible that
changes in the subcellular distribution of annexin A2 in the
S100A10-null macrophages could account for the decreased
annexin A2 levels.
7.3. S100A10 in Oncogenesis. Oncogenesis, the process of
tumor development and progression, requires an inti-
mate association between the cancer cells and the tumor-
associated cells. The cancer cells utilize plasmin and other
proteases such as cathepsin B and the matrix metallo-
proteases (MMPs) to proteolyse the extracellular matrix
and basement membrane in order to gain access to the
circulation. Once in the circulation, the cancer cells utilize
proteolytic activity to enter and form stable metastatic
foci in other tissues. The tumor-associated cells such as
macrophages also require proteolytic activity in order to
migrate from the circulation into the tumor stroma. There-
fore, proteolytic activity is used by both cancer cells and
tumor-associated cells during oncogenesis. Several studies
have established that plasmin is an important protease
involved in cancer cell migration and invasion, but the
plasminogen receptor(s) that is involved in the regulation of
plasmin activation during oncogenesis remains elusive.
The uPA receptor, uPAR, is an important regulator of
plasmin-dependent extracellular matrix proteolysis in cancer
cells. uPAR binds uPA and its zymogen form, pro-uPA,
and therefore localizes these proteins to the cell surface
[143]. Activated uPA that is bound to the uPAR at the
cell surface cleaves plasminogen and the resultant plasmin
reciprocally cleaves and activates pro-uPA (Figure 1). This
positive-feedback loop is further amplified by the increased
concentration of the active and zymogen forms of uPA and
plasmin at the cell surface through uPA or pro-uPA binding
to the uPAR and plasminogen or plasmin binding to the
plasminogen receptor(s) (reviewed in [144–146]). Previous
work from our laboratory has shown that S100A10 co-
localizes with uPAR and positively regulates the conversion
of pro-uPA to active uPA [65]. The activation of proteases
at the cell surface of cancer cells plays an important role
in the migration of primary tumor cells as well as in the
invasiveness of these cells and establishment of metastatic
foci at other sites.
Several studies have shown that S100A10 plays an
important role in tumor invasion and metastasis. Choi and
colleagues have shown that mice injected with S100A10-
depleted HT-1080 fibrosarcoma cells have a 3-fold decrease
in the number of metastatic foci in the lungs compared
to mice injected with control HT1080 cells, while overex-
pression of S100A10 in the HT-1080 cells leads to a 16-
fold increase in the number of lung metastasis in these
mice [64]. Furthermore, tumor formation in SCID mice
was dramatically reduced in S100A10-antisense-transfected
HT-1080 cells compared to the vector control (Figure 7).
These results show that the ability of HT-1080 tumor
cells to extravasate and metastasize is directly related to
the extracellular expression of S100A10. Another study
showed that siRNA-mediated downregulation of S100A10
gene expression in CCL-222 colorectal cancer cells resulted
in a significant decrease in extracellular S100A10 protein,
which correlated with a 45% loss in plasminogen binding
and a 65% loss in cellular plasmin generation in these cells
compared to the control cells. S100A10 depletion in CCL-222
cells also abolished the plasminogen-dependent invasiveness
of these cells through a matrigel barrier. A remarkable
observation made by this study was that the CCL-222 cells
do not express annexin A2 on their extracellular surface and
for this reason the plasminogen binding, plasmin activation
and invasiveness of these cells, although dependent on the
presence of S100A10 at the cell surface, were independent
of annexin A2. Collectively, these studies establish a role for
S100A10 as an oncogenic plasminogen receptor, involved in
invasiveness and metastasis of cancer cells.
7.4. The Role of S100A10 in the Migration of Macrophages to
the Tumor Site. Inflammatory cell recruitment to the tumor
microenvironment is indispensable to cancer progression.
Tumor-associated macrophages (TAMs) represent a promi-
nent component of the inflammatory cell population with
solid tumors and density of TAMs within a tumor correlates
with poor prognosis [147]. The recruitment of TAMs to
the tumor microenvironment involves the migration of
monocytic precursor cells from the circulation in response
to various chemotactic signals originating from the tumor
[148]. TAMs promote tumor growth by mediating inflam-
mation, stimulating angiogenesis, suppressing antitumor
immunity, and by matrix remodeling [149]. However, little
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is known about the proteolytic mechanism by which mono-
cytes/macrophagesmigrate from the circulation to the tumor
site. Several studies have hypothesized that macrophages
mobilize a number of cell surface plasminogen receptors to
generate plasmin thereby facilitating proteolysis of basement
membrane and extracellular matrices to allow migration to
the tumor site. Recently, O’Connell et al. [67] demonstrated
that S100A10 plays a significant role in mediating plasmin
generation at the surface of macrophages.
Phipps et al. [68] recently demonstrated that S100A10
plays a significant role in oncogenesis. Wild-type and
S100A10-null mice were injected with Lewis Lung carcinoma
cells and the kinetics of tumor growth was measured. Inter-
estingly, tumors grown in the S100A10-null mice reached
maximum size after seven days whereas tumors in their
wild-type counterparts continued to grow exponentially.
Upon termination of the experiment, LLC tumors from
wild-type mice were 10-fold larger than those in S100A10-
null mice. Immunohistochemical analysis of the tumors
revealed that macrophage recruitment was impaired in the
S100A10-null mice. Macrophages were visible throughout
wild-type tumors but were only found at the tumor
edge in S100A10-null mice. Cytokine levels were similar
in wild-type and S100A10 tumors thus eliminating the
possibility that less macrophages were recruited due to
impaired chemokine/cytokine production. Peritoneal injec-
tion of wild-type macrophages into S100A10-null mice prior
to injection of LLC cells rescued tumor growth to levels
comparable to those seen in wild-type mice, indicating that
S100A10-null plays an important role in both angiogene-
sis and tumor growth in terms of macrophage function.
Taken together, these studies demonstrated that expression
of S100A10 on the surface of murine macrophages plays
significant role in their ability to associate with the tumor
microenvironment and, in turn, promotes tumor growth and
progression, that is, oncogenesis.
7.5. Regulation of S100A10 by the Oncogene PML-RARα.
Leukemia is a group of hematological malignancies char-
acterized by clonal expansion of hematopoietic cells with
uncontrolled proliferation, blocked diﬀerentiation, and
decreased apoptosis. Acute myeloid leukemia (AML) is the
most common leukemia aﬀecting adults. Acute promye-
locytic leukemia (APL) is a subtype of acute myeloid
leukemia that is characterized by fusion of the retinoic acid
receptor alpha (RARα) gene with the promyelocytic leukemia
(PML) gene via the t(15; 17) translocation, resulting in the
expression of a PML-RARα fusion protein [150]. Intracel-
lular accumulation of the PML-RARα fusion protein causes
the inhibition of cellular diﬀerentiation of these cells into
granulocytes, resulting in the accumulation of the abnormal
promyelocytes in the bone marrow. Pathogenesis of the dis-
ease includes disseminated intravascular coagulation (DIC),
fibrinolysis, and proteolysis. The excessive fibrinolysis and
proteolysis is thought to be a result of increased production
of the fibrinolytic enzyme plasmin, and clinical evidence
supports this idea. It is common for patients with new
diagnoses of APL to present with elevated D-dimer level,
fibrin split products, elevated prothrombin time and partial
thromboplastin time, and hypofibrinogenemia [151–153].
Because activation of plasmin at the cell surface is necessary
for plasmin activity, attention has turned to elucidating the
plasminogen receptor on APL cells.
Previous work has shown that annexin A2 levels are
elevated in APL and annexin A2 protein levels have been
implicated as the cause for the excessive fibrinolysis that is
associated with the disease. It was previously observed that
all-trans retinoic acid (ATRA) treatment of APL primary
cells and cell lines resulted in loss of cell surface annexin
A2. In vitro treatment of t(15; 17)-positive APL cells with
all-trans-retinoic acid significantly reduced both the cellular
expression of annexin A2 and plasmin generation over
a similar period [154, 155]. However, since annexin A2
knockdown results in concomitant loss of S100A10, it is
diﬃcult to attribute these eﬀects to annexin A2 or S100A10.
Of the reputed plasminogen receptors, annexin A2 was
reported to be present at abnormally high levels on APL cells
and it was proposed that the elevated levels of annexin A2
were responsible for increased production of plasmin and
the hemorrhagic complications of APL. A recent publication
from our laboratory examined the role of S100A10 in regu-
lating the generation of plasmin at the surface of APL cells in
NB4 cells [29]. We used the human APL cell line, NB4, for
these studies. NB4 cells possess the t(15; 17)-translocation
and constitutively express the PML-RARα oncoprotein and
are induced to terminally diﬀerentiate to neutrophils with
ATRA. Depletion of S100A10 by RNA interference resulted in
a 70% loss in plasminogen binding and a 64% loss in plasmin
generation by the NB4 cells. Furthermore, depletion of
S100A10 resulted in 60% fewer NB4 cells migrating through
a fibrin barrier. These results established the importance of
S100A10 in plasmin generation in promyelocytic leukemia
cells. Treatment of the NB4 cells with ATRA resulted in a
rapid reduction in the PML-RARα oncoprotein concomitant
with a loss of S100A10. ATRA treatment also resulted in a
60% loss in plasminogen binding, a 40% loss in plasmin
activity, and a 60% loss in migration of the ATRA-treated
NB4 cell through the fibrin barrier. The complete loss of
cellular levels of S100A10 after ATRA treatment presents the
possibility that the remission of hemorrhagic complications
observed during treatment of APL patients with ATRA could
be due to the ATRA-mediated loss of S100A10 from the
surface of the leukemic promyelocytes.
Since the treatment of NB4 cells with ATRA is known
to result in the upregulation of about 119 genes as well as
the downregulation of 17 genes [156], it was unclear if the
regulation of S100A10 by ATRA was directly regulated by
the PML-RARα oncoprotein or by other ATRA-regulated
genes. This issue was directly addressed by examining
S100A10 levels in the U937/PR9 cells, which express PML-
RARα oncoprotein under the control of a zinc-inducible
promoter. Expression of PML-RARα oncoprotein resulted
in a rapid and dramatic upregulation of S100A10 protein
and a subsequent increase in plasminogen binding and
fibrinolytic activity. We also observed that annexin A2
was upregulated by induced expression of the PML-RARα
oncoprotein. However, when the PML-RARα oncoprotein-
expressing PR9 cells were depleted of S100A10 by RNA
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interference, we observed a dramatic loss of plasminogen
binding and plasmin generation [29]. These data suggest
that PML-RARα oncoprotein increases the S100A10 protein
levels and also implicate S100A10 as a major component of
the fibrinolytic system upon development of APL. Therefore,
the upregulation of S100A10 at the cell surface of promye-
locytic leukemic cells is likely the cause of the bleeding
complications that are associated with APL.
These results demonstrated, for the first time, the
regulation of S100A10 protein levels by an oncogene. A study
performed by Sloane’s laboratory showed that disruption of
the gene that encodes oncogenic K-Ras, a well established
oncogene, results in a dramatic decrease in S100A10 protein
levels [157]. This result suggests that S100A10 protein levels
might also be stimulated by oncogenic Ras and that S100A10
might play a role in Ras-dependent plasmin activation and,
consequently, cancer cell invasiveness. Nevertheless, further
studies are necessary in order to address this hypothesis.
8. Summary
The evidence that has accumulated over the past 15 years
supports the concept that one of the most important
physiological functions of S100A10 is as a plasminogen
receptor. As such, S100A10 plays an important role in
endothelial cell function by regulating plasmin production.
In the absence of S100A10, endothelial cells fail to produce
suﬃcient plasmin to maintain vascular patency and as a
consequence fibrin clots accumulate in the tissues. S100A10
also regulates the movement of macrophages to the site of
inflammation. S100A10 also plays a key role in oncogenesis
by regulating the plasmin proteolytic activity of cancer cells
and by regulating themigration ofmacrophages to the tumor
site. The regulation of S100A10 levels by oncogenes such
as PML-RARα and oncogenic KRas presents the possibility
that activation of the S100A10 gene may be of fundamental
importance during the transformation process. Future stud-
ies are necessary to define exactly when during the cellular
transformation process the S100A10 gene is activated and
what are the functional consequences of that activation.
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